Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
July 16, 2018 at 16:16 PM EDT
The two companies, which said a licensing deal in 2014, have completed the transfer of the therapy's development from Spark to Pfizer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.